Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: Toxicity, bioavailability and the effect of food

Clinical Cancer Research

Volumn 8, Issue 1, 2002, Pages 86-94

  Berlin, Jordan ^a   Tutsch, Kendra D ^a   Arzoomanian, Rhoda Z ^a   Alberti, Dona ^a   Binger, Kim ^a   Feierabend, Chris ^a   Dresen, Amy ^a   Marnocha, Rebecca ^a   Wilding, George ^a   Pluda, James ^b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE;

ADULT; AGED; ARTICLE; CALCIUM SIGNALING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOOD INTAKE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEADY STATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CALCIUM; CALCIUM CHANNEL BLOCKERS; CAPSULES; DIET THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; GELS; HEMATOPOIESIS; HUMANS; INTESTINAL ABSORPTION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NERVOUS SYSTEM; TRIAZOLES;

EID: 0036155275     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates
2. In hibitory effects of CAI in glioblastoma growth and invasion
3. Antiproliferative and antiinvasive effects of carboxyamido-triazole on breast cancer cell lines
4. Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines
5. The inhibition of receptor - Mediated and voltage-dependent calcium entry by the antiproliferative L-651, 582
6. Angiogenesis: Role of calcium-mediated signal transduction
7. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor
8. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers
9. Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: Use of a single model for simultaneous determination of changing parameters
10. Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: Pharmacokinetics, clinical outcome, and comparison of formulations
11. Physician-determined patient risk of toxic effects: Impact on enrollment and decision making in phase I cancer trials
12. The limited precision of phase trials
13. L651582: A novel antiproliferative and antimetastasis agent
14. A pharmacokinetically guided Phase II study of carboxyamidotriazole in androgen-independent prostate cancer
15. Retinal toxicity after high-dose cisplatin therapy
16. Natural history and therapy of renal cell carcinoma: The role of interleukin-2